[1] Prognostic values of serum galactomannan and  (1-3)-beta-D-glucan in hospitalised patients: analysis of initial and follow-up results. Park et al. (2019) ECCMID, P0131                        

[2] Evaluation of CrAg lateral flow immunoassay for diagnosis of cryptococcal meningitis patients. Zhang Q. Q. (2018) ECCMID, P1198

[3] VALUTAZIONE DI DUE METODICHE PER IL DOSAGGIO SIERICO DEL 1,3-β-D-GLUCANO IN PAZIENTI A RISCHIO DI INFEZIONI FUNGINE INVASIVE. Cipriani R., Brossa S., Zanotto E. et al. (2017)

[4] VALUTAZIONE DI UN NUOVO TEST GOLDSTREAM FUNGUS (1,3)-ß-D-Glucano PER LA DIAGNOSTICA DELLE INFEZIONI FUNGINE INVASIVE. De Nittis R., Delli Carri V., Trecca A. et al. (2017)

[5] Diagnostic performance of the (1-3)-β-D-glucan assay in patients with Pneumocystis jirovecii compared with those with candidiasis, aspergillosis, mucormycosis, and tuberculosis, and healthy volunteers. Son H J, Sung H, Park S Y, et al., (2017), PLoS One. 2017 Nov 30;12(11):e0188860. 

[6] Diagnostic Performance of the (1–3)-β-D-Glucan Assay in Pneumocystitis jirovecii, Invasive Aspergillosis, Mucormycosis, Tuberculosis and Healthy Volunteers. Son H J, Sung H, Park S Y, et al., (2016), Open Forum Infectious Diseases. Oxford University Press, 3(suppl 1): 1562.

[7] New galactomannan assay for invasive aspergillus diagnosis in high risk patients received anti-cancer therapies in China. Zhang, P., Zhang, W., Li, D. (2016) American Society for Microbiology

[8] Statistical assessment of Tachypleus amoebocyte lysate for early diagnosis of invasive fungal disease at an ICU in China. Qin, Z., Y Ji., Zhang, A., D., LI, J., Liu, D., Wang, Z., Y., Wang, C., X. (2016) ECCMID

[9] Emergence of TR46/Y121F/T289A in an Aspergillus fumigatus Isolate from a Chinese Patient. Chen Y, Wang H, Lu Z, et al., (2015), Antimicrobial Agents & Chemotherapy, 59(11):7148.

[10] Serum Levels of Lipopolysaccharide and 1, 3-β-D-Glucan Refer to the Severity in Patients with Crohn’s Disease. Guo Y, Zhou G, He C, et al., (2015), Mediators of inflammation

[11] The screening performance of serum 1, 3-beta-D-glucan in patients with invasive fungal diseases: a meta-analysis of prospective cohort studies. Hou, T., Y., Wang, S., H., Liang, S., X., Jiang, W., X., Luo, D., D., Huang, D., H, (2015) PLoS ONE 10(7): e0131602.

[12] Platelet parameters and (1, 3)-β -D-glucan as a diagnostic and prognostic marker of invasive fungal disease in preterm infants. Zhao, D., Y., Qiu, G., Luo, Z., C., Zhang, Y., J. (2015). PLoS ONE 10(4): e0123907.

[13] Evaluation of a novel plasma (1, 3)-β-d-glucan detection assay for diagnosis of candidemia in pediatric patients. Liu, Y., Chen, F., Zhu, X., Shen, L., & Zhang, S. X. (2015). Journal of Clinical Microbiology, 53(9), 3017-3020.

[14] The serum glucan level and pathological changes of antifungal treatment for lower respiratory tract infection of Candida albicans. Xu W M, Shui W, Lin J C, et al. Medical mycology, (2014): myu068.

[15] Risk factors for recurrence of invasive fungal infection during secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients. Liu F, Wu T, Wang J B, et al., (2013), Transplant Infectious Disease, 15(3): 243-250.

[16] Laboratory diagnosis of invasive aspergillosis: from diagnosis to prediction of outcome. Barton, R., C. (2013) Scientifica

[17] Diagnostic accuracy of serum 1, 3-β-d-glucan for pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis. Onishi, A., Sugiyama, D., Kogata, Y., Saegusa, J., Sugimoto, T., & Kawano, S., et al. (2012) Journal of Clinical Microbiology, 50(1), 7-15.